



NDA 019125/S-042

SUPPLEMENT APPROVAL

Xttrium Laboratories
Attention: Joe Scalise
Director of Quality Assurance/
Regulatory Affairs
1200 East Business Center Drive
Mount Prospect, Illinois 60056

Dear Mr. Scalise:

Please refer to your Supplemental New Drug Application (sNDA) dated and received on April 15, 2014 submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Dyna-Hex 4 (chlorhexidine gluconate 4% solution).

We acknowledge receipt of your amendments dated May 2 and 7, 2014.

This Prior Approval sNDA proposes to add the following statement to the principal display panel of the “Compare to the active ingredient in Hibiclens®” on the principal display panel.

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

LABELING

Submit final printed labeling (FPL), as soon as they are available, but no more than 30 days after they are printed. The FPL must be identical to the 8 oz. immediate container submitted on May 7, 2014 and must be in the “Drug Facts” format (21 CFR 201.66), where applicable.

The FPL should be submitted electronically according to the guidance for industry titled “Providing Regulatory Submissions in Electronic Format – Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (June 2008).” Alternatively, you may submit 12 paper copies, with 6 of the copies individually mounted on heavy-weight paper or similar material. For administrative purposes, designate this submission **“Final Printed Labeling for approved NDA 019125/S-042.”** Approval of this submission by FDA is not required before the labeling is used.

DRUG REGISTRATION AND LISTING

All drug establishment registration and drug listing information is to be submitted to FDA electronically, via the FDA automated system for processing structured product labeling (SPL) files (eLIST). At the time that you submit your final printed labeling (FPL), the content of labeling (Drug Facts) should be submitted in SPL format as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Information on submitting SPL files using eLIST may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As" at <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>. In addition, representative container or carton labeling, whichever includes Drug Facts, (where differences exist only in the quantity of contents statement) should be submitted as a JPG file.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Celia Peacock, Regulatory Project Manager at (301) 796-4154.

Sincerely,

{See appended electronic signature page}

Theresa Michele, M.D.
Director
Division of Nonprescription Clinical Evaluation
Office of Drug Evaluation IV
Center for Drug Evaluation and Research

ENCLOSURE:

Immediate Container Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

THERESA M MICHELE
10/17/2014